IDWeek 2019 — Low predictive value of beta-D-glucan in hematology patients on antifungal prophylaxis


  • Devona Williams, Pharm.D.
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Beta-D-glucan has a low positive predictive value for diagnosis of invasive fungal infection in hematology patients prescribed antifungal prophylaxis.

Why this matters

  • Patients treated with induction chemotherapy or stem cell transplant for hematologic malignancies require antifungal prophylaxis.
  • Beta-D-glucan (BDG) is a common method of surveillance for diagnosis of suspected invasive fungal infections.

Study design

  • Retrospective chart review of all BDG results in hematology patients receiving posaconazole or micafungin prophylaxis.
  • BDG results were categorized at true-positive, true-negative, false-positive, or false-negative.
  • Indications for diagnostic screening:
    • Neutropenic fever >5 days in setting of broad-spectrum antibacterial agents.
    • Clinical symptoms and diagnostic imaging suggesting fungal infection.

Key results

  • Most patients had received either a stem cell transplant (49.7%) or induction chemotherapy (43.8%).
  • The rate of true-positive BDG confirmation of infection was low. 
  • The negative predictive value of BDG was 95.7%.
  • The sensitivity was 42.9% and the specificity was 88.1%.
  • BDG was useful in excluding fungal infection, but not effective for infection diagnosis.

Limitations

  • Single-center, retrospective chart review.
  • Results presented at a conference and not peer-reviewed.

 

 

 

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit